Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $69,794 | $45,769 | $77,851 | $230,219 |
| - Cash | $35,405 | $41,895 | $39,154 | $39,818 |
| + Debt | $2,989 | $3,263 | $3,514 | $3,645 |
| Enterprise Value | $37,378 | $7,137 | $42,211 | $194,046 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$300 | -$300 | -$311 | -$303 |
| % Margin | – | – | – | – |
| EBITDA | -$17,934 | -$20,706 | -$19,369 | -$22,528 |
| % Margin | – | – | – | – |
| Net Income | -$18,234 | -$21,006 | -$19,680 | -$22,831 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.47 | -0.55 | -0.51 | -0.6 |
| % Growth | 14.5% | -7.8% | 15% | – |
| Operating Cash Flow | -$12,283 | -$16,610 | -$19,535 | -$17,360 |
| Capital Expenditures | -$899 | -$493 | -$58 | -$827 |
| Free Cash Flow | -$13,182 | -$17,103 | -$19,593 | -$18,187 |